Inhibition of Lipopolysaccharide-stimulated Inflammatory Cytokine Production by LY303511 in Human Macrophagic THP-1 Cells
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
We have previously shown that the specific phosphatidylinositol 3-kinase inhibitor LY294002 (LY29), and its inactive analog LY303511 (LY30), inhibit a monocyte chemoattractant protein-1 (MCP-1) expression in human umbilical vein endothelial cells; these results suggest the potential of LY30 as an anti-inflammatory drug. In this study, we determined the effects of LY30 on the production of various inflammatory cytokines in human macrophagic THP-1 cells which were stimulated with lipopolysaccharide (LPS). LY30 selectively suppressed the mRNA expression of IL-12 p40, TNF-α, and MCP-1 without affecting the expression of IL-1α, IL-6, and IL-8. Inhibition of the production of IL-12 and TNF-α by LY30 was also demonstrated using ELISA assays. In order to elucidate the mechanisms of the action of LY30, we examined the role played by the mitogen-activated protein kinases and the key transcription factors, AP-1 and NF-κB in LPS-stimulated THP-1 cells. The results revealed that LY30 inhibited LPS-induced activation of ERK, but not p38 or JNK. Furthermore, the AP-1 DNA binding activity was suppressed by LY30 based upon the dosage, whereas NF-κB DNA binding was not affected. These results suggest that LY30 selectively inhibits cytokine production in the LPS-stimulated macrophagic THP-1 cells by downregulating the activation of ERK and AP-1.
Abstract
We have previously shown that the specific phosphatidylinositol 3-kinase inhibitor LY294002 (LY29), and its inactive analog LY303511 (LY30), inhibit a monocyte chemoattractant protein-1 (MCP-1) expression in human umbilical vein endothelial cells; these results suggest the potential of LY30 as an anti-inflammatory drug. In this study, we determined the effects of LY30 on the production of various inflammatory cytokines in human macrophagic THP-1 cells which were stimulated with lipopolysaccharide (LPS). LY30 selectively suppressed the mRNA expression of IL-12 p40, TNF-α, and MCP-1 without affecting the expression of IL-1α, IL-6, and IL-8. Inhibition of the production of IL-12 and TNF-α by LY30 was also demonstrated using ELISA assays. In order to elucidate the mechanisms of the action of LY30, we examined the role played by the mitogen-activated protein kinases and the key transcription factors, AP-1 and NF-κB in LPS-stimulated THP-1 cells. The results revealed that LY30 inhibited LPS-induced activation of ERK, but not p38 or JNK. Furthermore, the AP-1 DNA binding activity was suppressed by LY30 based upon the dosage, whereas NF-κB DNA binding was not affected. These results suggest that LY30 selectively inhibits cytokine production in the LPS-stimulated macrophagic THP-1 cells by downregulating the activation of ERK and AP-1.
참고문헌 (15)
- Saleh Adi, "Growth factor-stimulated phosphorylation of Akt and p70(S6K) is differentially inhibited by LY294002 and Wortmannin", Endocrinology, 142(1), pp.498~501 (2001), The Endocrine Society[DOI]
- Arcaro A, "Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor : the role of phosphatidylinositol 3, 4, 5-trisphosphate in neutrophil responses", Biochem J, 296, pp.297~301 (1993)
- Vlahos CJ, "A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one(LY294002)", J Biol Chem, 269, pp.5241~5248 (1994)
- Eun-Kyoung Choi, "LY294002 inhibits monocyte chemoattractant protein-1 expression through a phosphatidylinositol 3-kinase-independent mechanism", FEBS Letters, 559(1-3), pp.141~144 (2004), Wiley[DOI]
- A. S. Kristof, "LY303511 (2-Piperazinyl-8-phenyl-4H-1-benzopyran-4-one) Acts via Phosphatidylinositol 3-Kinase-Independent Pathways to Inhibit Cell Proliferation via Mammalian Target of Rapamycin (mTOR)- and Non-mTOR-Dependent Mechanisms", Journal of Pharmacology and Experimental Therapeutics, 314(3), pp.1134~1143 (2005), American Society for Pharmacology & Experimental Therapeutics (ASPET)[DOI]
- Tze Wei Poh, "LY294002 and LY303511 Sensitize Tumor Cells to Drug-Induced Apoptosis via Intracellular Hydrogen Peroxide Production Independent of the Phosphoinositide 3-Kinase-Akt Pathway", Cancer Research, 65(14), pp.6264~6274 (2005), American Association for Cancer Research (AACR)[DOI]
- Avni D, "The phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 modulates cytokine expression in macrophages via p50 nuclear factor-κB inhibition, in a PI3K-independent mechanism", Biochem Pharmacol, 83, pp.106~114 (2011)[DOI]
- Tas SW, "Recent Advances in the Treatment of Immune-Mediated Inflammatory Diseases", Methods Mol Biol, 1371, pp.143~155 (2016)[DOI]
- Guillermo Arango Duque, "Macrophage Cytokines: Involvement in Immunity and Infectious Diseases", Frontiers in Immunology, 5, pp.491~ (2014), Frontiers Media SA[DOI]
- Auwerx J, "The human leukemia cell line, THP-1 : a multifacetted model for the study of monocyte-macrophage differentiation", Experientia, 47, pp.22~31 (1991)
- Zhang YL, "MAP kinases in immune responses", Cell Mol Immunol, 2, pp.20~27 (2005)
- Adcock IM, "Transcription factors as activators of gene transcription : AP-1 and NF-κB", Monaldi Arch Chest Dis, 52, pp.178~186 (1997)
- Sivakumar Vallabhapurapu, "Regulation and Function of NF-κB Transcription Factors in the Immune System", Annual Review of Immunology, 27(1), pp.693~733 (2009), Annual Reviews[DOI]
- Eun-Kyoung Choi, "Enhancement of cytokine-mediated NF-κB activation by phosphatidylinositol 3-kinase inhibitors in monocytic cells", International Immunopharmacology, 6(6), pp.908~915 (2006), Elsevier BV[DOI]
- Robert Roskoski, "ERK1", 2 MAP kinases: Structure, function, and regulation, 2012, pp.66(2), 105~143[DOI]